Safety Profile
Known Safety Concerns
- Avoid in severe immunocompromise (chemotherapy, organ transplant immunosuppression)
- Rare: temporary bloating and gas as microbiome adjusts
- Live bacteria -- check viability (CFU count) at expiration
- Generally extremely safe for healthy adults
Contraindications
- Avoid in severe immunocompromise (chemotherapy, organ transplant immunosuppression)
- Rare: temporary bloating and gas as microbiome adjusts
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Bifidobacterium longum is a well-studied probiotic strain with evidence supporting immune modulation, reduction of anxiety, and improvement in bowel regularity. It is one of the predominant bacteria in the infant colon. Generally considered safe for healthy adults. Caution is warranted in severely immunocompromised individuals, as with all live microbial supplements.
Biological and Chemical Classification
- Scientific Name
- Bifidobacterium longum
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Probiotic
- Evidence consistency: High consistency across studies (100%)
- Avoid in severe immunocompromise (chemotherapy, organ transplant immunosuppression)
- Rare: temporary bloating and gas as microbiome adjusts
- Live bacteria -- check viability (CFU count) at expiration
- Generally extremely safe for healthy adults
The available scientific evidence for Bifidobacterium Longum indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 12:48
Evidence Distribution
-
Observational / other LOW evidence YELLOWMetabolic pathway analysis reveals hierarchical pentose sugar utilization and metabolic flexibility of Bifidobacterium longum. ↗Friess L et al.. Metabolic pathway analysis reveals hierarchical pentose sugar utilization and metabolic flexibility of Bifidobacterium longum.. Gut Microbes. 2026. PMID:41872067.PMID 41872067 ↗Journal Gut MicrobesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41872067/
-
Observational / other LOW evidence YELLOWComparative Immunomodulatory Profiles of Bifidobacterium animalis subsp. lactis HOM2120 and Bifidobacterium longum subsp. longum HOM1190: Insights from Genomics, In Vitro, and In… ↗Wang T et al.. Comparative Immunomodulatory Profiles of Bifidobacterium animalis subsp. lactis HOM2120 and Bifidobacterium longum subsp. longum HOM1190: Insights from Genomics, In Vitro, and In Vivo Studies.. J Microbiol Biotechnol. 2026. PMID:41866907.PMID 41866907 ↗Journal J Microbiol BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41866907/
-
Observational / other LOW evidence YELLOWProbiotic Supplementation as an Alternative to Antibiotics in Bovine Sperm Cryopreservation: Effects on Motility, Oxidative Stress and Apoptosis. ↗u00d6mu00fcr AD et al.. Probiotic Supplementation as an Alternative to Antibiotics in Bovine Sperm Cryopreservation: Effects on Motility, Oxidative Stress and Apoptosis.. Reprod Domest Anim. 2026. PMID:41853987.PMID 41853987 ↗Journal Reprod Domest AnimYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41853987/
-
Observational / other LOW evidence YELLOWThe potential of Bifidobacterium longum subsp. infantis in ameliorating traumatic brain injury-induced cognitive impairment in mice. ↗He D et al.. The potential of Bifidobacterium longum subsp. infantis in ameliorating traumatic brain injury-induced cognitive impairment in mice.. Exp Neurol. 2026. PMID:41833795.PMID 41833795 ↗Journal Exp NeurolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41833795/
-
Observational / other LOW evidence YELLOWHigh dietary fiber is associated with improved outcomes in patients with melanoma and sarcoma treated with immunotherapy regardless of gut microbiome dysbiosis… ↗Fields BC et al.. High dietary fiber is associated with improved outcomes in patients with melanoma and sarcoma treated with immunotherapy regardless of gut microbiome dysbiosis and social vulnerability.. Cancer. 2026. PMID:41832741.PMID 41832741 ↗Journal CancerYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41832741/
-
Observational / other LOW evidence YELLOWHeat-Killed Bifidobacterium longum KABP-042 and Lactiplantibacillus Plantarum KABP-051 Prevent Scopolamine-Induced BDNF Reduction and Memory Impairment in Mice. ↗Fukuchi M et al.. Heat-Killed Bifidobacterium longum KABP-042 and Lactiplantibacillus Plantarum KABP-051 Prevent Scopolamine-Induced BDNF Reduction and Memory Impairment in Mice.. Cell Biochem Biophys. 2026. PMID:41831189.PMID 41831189 ↗Journal Cell Biochem BiophysYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41831189/
-
Observational / other LOW evidence YELLOWBifidobacterium Mediates the Associations Between the Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure and Blood Lipids in Chinese Adults. ↗Zhang Q et al.. Bifidobacterium Mediates the Associations Between the Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure and Blood Lipids in Chinese Adults.. Nutrients. 2026. PMID:41829967.PMID 41829967 ↗Journal NutrientsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41829967/
-
Observational / other LOW evidence YELLOWProtective Effect of Bifidobacterium longum subsp. infantis E4 Exopolysaccharide on Intestinal Barrier, Regulation of Gut Microbiota and Metabolite In Vitro, and Immunosuppressed… ↗Wang Y et al.. Protective Effect of Bifidobacterium longum subsp. infantis E4 Exopolysaccharide on Intestinal Barrier, Regulation of Gut Microbiota and Metabolite In Vitro, and Immunosuppressed Mice.. J Agric Food Chem. 2026. PMID:41811065.PMID 41811065 ↗Journal J Agric Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41811065/
-
Observational / other LOW evidence YELLOWGut bacterial and fungal signatures in relation to human leukocyte antigen-DQ2/DQ8 in children with celiac disease and siblings. ↗Salamon D et al.. Gut bacterial and fungal signatures in relation to human leukocyte antigen-DQ2/DQ8 in children with celiac disease and siblings.. World J Gastroenterol. 2026. PMID:41809456.PMID 41809456 ↗Journal World J GastroenterolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41809456/
-
Observational / other LOW evidence YELLOWBifidobacterium longum subsp. infantis B8762 modulates the infant gut-lung axis via microbial and metabolic reprogramming. ↗Ma R et al.. Bifidobacterium longum subsp. infantis B8762 modulates the infant gut-lung axis via microbial and metabolic reprogramming.. Microb Pathog. 2026. PMID:41802657.PMID 41802657 ↗Journal Microb PathogYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41802657/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Bifidobacterium Longum. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Bifidobacterium Longum
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.